FDA Approves Gazyva for Idiopathic Nephrotic Syndrome in Patients Aged 2 and Older

RegulatoryapprovedGazyvaPositive

AI Analysis

Summary

The FDA has approved Genentech's Gazyva (obinutuzumab) to reduce the risk of relapse in idiopathic nephrotic syndrome in patients aged 2 and older, expanding the drug's approved uses.

Outcome Details

FDA approved Gazyva to reduce the risk of relapse in idiopathic nephrotic syndrome in patients aged 2 and older

Importance:8/10

Sentiment:

0.85

FDA approvalobinutuzumabidiopathic nephrotic syndromepediatric indication

Related Companies

$RHHBY

Read the original article

Published by Drugs.com New Drug Approvals on September 25, 2026 9:09 PM

Read Original